Vol 69, No 2 (2018)
Original paper
Published online: 2017-12-20

open access

Page views 4027
Article views/downloads 2337
Get Citation

Connect on Social Media

Connect on Social Media

The impact of serum adropin and ischemia modified albumin levels based on BMI in PCOS

Zeynep Ozturk Inal1, Sami Erdem1, Yavuz Gederet1, Cevdet Duran1, Zehra Kucukaydin1, Huseyin Kurku1, Derya Kilic Sakarya1
Pubmed: 29465156
Endokrynol Pol 2018;69(2):135-141.


Introduction: The aim of this study was to evaluate the effects of polycystic ovary syndrome (PCOS) and body mass index (BMI) on serum adropin and ischemia modified albumin (IMA) levels. Materials and methods: This prospective cross-sectional study was performed with a total of 120 women [group1; non-PCOS = 60 (BMI < 25 = 30, BMI ≥25 = 30) and group 2; PCOS = 60 (BMI < 25 = 30, BMI ≥25 = 30)]. Blood samples were collected between the third and fifth days of the women’s menstrual cycles after a night of fasting. Results: There were no differences between the groups in relation to age, basal follicle stimulating hormone, estradiol, thyroid stimulating hormone, prolactin, high-density lipoprotein cholesterol, total testosterone, dehydroepiandrosterone sulfate levels, systolic and diastolic blood pressures. A significant difference was found in basal luteinizing hormone, fasting glucose, insulin, homeostatic model assessment of insulin resistance, total cholesterol, low-density lipoprotein cholesterol, triglycerides, free testosterone levels, waist-to-hip ratios and the Ferriman-Gallwey scores between the PCOS and non-PCOS patients in the lean and overweight groups (p < 0.05). The serum adropin levels in the lean PCOS group were lower than in the lean non-PCOS group (p < 0.05) and were lower in the overweight PCOS group than in the overweight non-PCOS group (p < 0.05). There was also a statistically significant difference in serum IMA levels in the PCOS group than in the non-PCOS group in both the lean and overweight groups (p < 0.05). Conclusions: Although serum adropin levels were significantly decreased in the PCOS group, IMA levels increased. Further studies are needed to determine the effects of adropin and IMA in women with PCOS and to use a new marker to monitorize treatment outcomes. < /p > < p >

Article available in PDF format

View PDF Download PDF file


  1. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89(6): 2745–2749.
  2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005; 352(12): 1223–1236.
  3. Lovren F, Pan Yi, Quan A, et al. Adropin is a novel regulator of endothelial function. Circulation. 2010; 122(11 Suppl): S185–S192.
  4. Inal HA, Yilmaz N, Gorkem U, et al. The impact of follicular fluid adiponectin and ghrelin levels based on BMI on IVF outcomes in PCOS. J Endocrinol Invest. 2016; 39(4): 431–437.
  5. Kume T, Calan M, Yilmaz O, et al. A possible connection between tumor necrosis factor alpha and adropin levels in polycystic ovary syndrome. J Endocrinol Invest. 2016; 39(7): 747–754.
  6. Beyazit F, Yilmaz N, Balci O, et al. Evaluation of Oxidative Stress in Women with Polycystic Ovarian Syndrome as Represented by Serum Ischemia Modified Albumin and Its Correlation with Testosterone and Insulin Resistance. Intern Med. 2016; 55(17): 2359–2364.
  7. Kumar KG, Trevaskis JL, Lam DD, et al. Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 2008; 8(6): 468–481.
  8. Aydin S, Kuloglu T, Aydin S, et al. Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem. 2013; 380(1-2): 73–81.
  9. Yildirim B, Celik O, Aydin S. Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome. Clin Exp Obstet Gynecol. 2014; 41(3): 310–312.
  10. Sayın O, Tokgöz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab. 2014; 27(5-6): 479–484.
  11. Gao Su, McMillan RP, Jacas J, et al. Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes. 2014; 63(10): 3242–3252.
  12. Celik E, Yilmaz E, Celik O, et al. Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med. 2013; 41(4): 375–380.
  13. Sen H, Erbag G, Bınnetoglu E, et al. Adropin Levels in Polycystic Ovary Syndrome Patients. J Clin Anal Med. 2017; 8: 23–6.
  14. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med. 2011; 49(2): 177–184.
  15. Duarte MM, Rocha JBT, Moresco RN, et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem. 2009; 42(7-8): 666–671.
  16. Cakir E, Ozbek M, Ozkaya E, et al. Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients. J Endocrinol Invest. 2011; 34(7): e178–e182.
  17. Ozturk M, Keskin U, Ozturk O, et al. Are serum gamma-glutamyl transferase, high-sensitivity C-reactive protein, and ischaemia-modified albumin useful in diagnosing PCOS? J Obstet Gynaecol. 2016; 36(7): 929–934.
  18. Caglar GS, Oztas E, Karadag D, et al. Ischemia-modified albumin and cardiovascular risk markers in polycystic ovary syndrome with or without insulin resistance. Fertil Steril. 2011; 95(1): 310–313.
  19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1): 19–25.
  20. FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 21: 1440–1447.
  21. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
  22. Mukherjee S, Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res. 2010; 131: 743–760.
  23. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005; 83(5): 1454–1460.
  24. Thathapudi S, Kodati V, Erukkambattu J, et al. Anthropometric and Biochemical Characteristics of Polycystic Ovarian Syndrome in South Indian Women Using AES-2006 Criteria. Int J Endocrinol Metab. 2014; 12(1): e12470.
  25. Kahyaoglu I, Yılmaz N, Timur H, et al. Granulocyte colony-stimulating factor: A relation between serum and follicular fluid levels and in-vitro fertilization outcome in patients with polycystic ovary syndrome. Cytokine. 2015; 74(1): 113–116.
  26. Hu W, Qiao J, Yang Y, et al. Elevated C-reactive protein and monocyte chemoattractant protein-1 in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011; 157(1): 53–56.
  27. Orvieto R, Chen R, Ashkenazi J, et al. C-reactive protein levels in patients undergoing controlled ovarian hyperstimulation for IVF cycle. Hum Reprod. 2004; 19(2): 357–359.
  28. Robinson S, Pemberton P, Laing I, et al. Low grade inflammation, as evidenced by basal high sensitivity CRP, is not correlated to outcome measures in IVF. J Assist Reprod Genet. 2008; 25(8): 383–388.
  29. Ganesh Kumar K, Zhang J, Gao Su, et al. Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring). 2012; 20(7): 1394–1402.
  30. Akcilar R, Kocak FE, Simsek H, et al. Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats. Bratisl Lek Listy. 2016; 117(2): 100–105.